Transforming Growth Factor Beta (TGFb) potently induces lens epithelial to mesenchymal transition (EMT). The resultant mesenchymal cells resemble those found in plaques of human forms of subcapsular cataract. Smad signaling has long been implicated as the sole driving force of TGFb-mediated activity. Rat lens epithelial explants were used to examine the role of the Smad-independent signaling, namely the MAPK/ERK1/2 signaling pathway, in the initiation and progression of TGFb-induced EMT. Phase contrast microscopy was used to observe the morphological changes associated with TGFb-induced EMT in this model, including cell elongation, cell membrane blebbing, cell loss as indicated by the area of bare capsule and capsular wrinkling. The levels of Smad2, Smad2/3 and ERK1/2 phosphorylation measured using western blotting confirmed that the addition of UO126 was sufficient in blocking all TGFb-induced ERK1/2 activation, as well as reducing Smad signaling at 18 h. Immunofluorescent labeling and further western blotting confirmed that TGFb-induced EMT was associated with an increase in a-smooth muscle actin (a-SMA) and a reduction of E-cadherin at cell borders. Pre-treatment with UO126 was effective at blocking the TGFb-induced EMT, as evidenced by a reduction of a-SMA expression and protein labeling, E-cadherin labeling at cell borders, and a reduction of cell loss, cell elongation and capsular wrinkling. Post-treatment with UO126 at 2 and 6 h after TGFb addition was also effective at blocking EMT while post-treatment with UO126 at 24 and 48 h was not sufficient in hampering TGFb-induced EMT. Our data implicates ERK1/2 signaling in the initiation but not the progression of TGFb-induced EMT in rat lens epithelial cells. The tight regulation of intracellular signaling pathways such as ERK1/2 are required for the maintenance of lens epithelial cell integrity and hence tissue transparency. A greater understanding of the molecular mechanisms that drive the induction and progression of EMT in the lens will provide the basis for potential therapeutics for human cataract.
Introduction
Cataract is the leading cause of blindness worldwide (Khairallah et al., 2015) , with aging being a leading contributing factor (Mukesh et al., 2006) . One form of cataract, Anterior Subcapsular Cataract (ASC) is primarily a pathology of the lens epithelium, characterized by multilayered cell aggregates that form anterior subcapsular plaques. The removal of such fibrotic cataracts and others through surgery can lead to secondary cataract, commonly known as Posterior Capsular Opacification (PCO) (see Wormstone et al., 2009 ).
The fibrotic morphologic and molecular features of ASC and PCO are similar and can be mimicked in vitro with the exposure of primary lens epithelial cells to Transforming Growth Factor beta (TGFb), resulting in an Epithelial to Mesenchymal Transition (EMT; Liu et al., 1994; Hales et al., 1994 Hales et al., , 1995 de Iongh et al., 2005) . The characteristic features of lens cells that have undergone an EMT include elongation into a spindle-shape with tapered ends, accumulation of a-smooth muscle actin (a-SMA) into stress fibers and changes to specialized cell-cell junctions leading to the loss of cell polarity and migration. Cell death through apoptosis is also a feature associated with TGFb-induced EMT that appears specific to lens epithelial explants (Liu et al., 1994; Lovicu et al., 2002; Maruno et al., 2002) .
Smad signal transduction is considered central to propagating TGFb signaling. Ligand binding activates the transmembrane TGFb receptor type II (TbR-II), enabling it to bind and activate TbR-I. Activation of these receptors facilitates the activation of receptorregulated Smad2 and Smad3 (R-Smads) through C-terminal serine/threonine kinase activity (Massague, 1998) . R-Smads consist of an N-terminal MH1 (MAD-Homology 1) and a C-terminal MH2 domain, joined by a linker region containing phosphorylation sites that facilitate cross-talk with non-Smad signaling pathways, such as ERK1/2 (Shi and Massague, 2003) . Once phosphorylated, the Smad2/3 complex with the co-effector, Smad4, enter the nucleus to facilitate gene transcription (Wrana and Attisano, 2000; Zhu and Burgess, 2001) . One mode of negative regulation of TGFbsignaling is the upregulation of the inhibitory Smad, Smad7, that terminates the TGFb signal by interrupting the R-Smad/Smad4 complex, or by directly antagonizing the TbRI (see Yan et al., 2009 ). Smad-independent signaling pathways have also been implicated in TGFb-induced EMT. For example, in NMuMG cells, TGFb-mediated ZO-1 and E-cadherin dissociation has been linked to PI3K/Akt signaling (Bakin et al., 2000) , and apoptosis has been shown to be p38/MAPK-dependent (Yu et al., 2002) . In a-TN4 mouse lens epithelial cells, TGFb-induced upregulation of a-SMA was shown to be through Snail via PI3K/Akt signaling, with ERK1/2 and p38 not playing a role in TGFb-induced EMT in this system (Cho et al., 2007) . Conversely in FHL124 human lens cells, TGFb has been shown to activate Smad-independent MAPK signaling pathways such as p38, JNK and ERK1/2 (Dawes et al., 2009 ); however, their direct function during TGFb-induced EMT has not been examined.
In the lens, MAPK/ERK1/2 signaling is associated with normal cellular processes of epithelial cell proliferation and differentiation (Lovicu and McAvoy, 2001 ; Le and Musil, 2001; Upadhya et al., 2013) . The conditional deletion of ERK2 in the developing mouse lens leads to disruption of cell proliferation and an increase in apoptosis (Upadhya et al., 2013) . Fibroblast growth factor (FGF) is the only known growth factor present in the ocular media that is able to induce both proliferation and differentiation of lens cells, via MAPK/ERK1/2 signaling, in a dose dependent manner (Lovicu and McAvoy, 2001; Le and Musil, 2001) . Given these distinct cellular responses are tightly regulated, so must FGF-induced ERK1/2 signaling. FGF ligand binding activates FGF receptor tyrosine kinases (RTKs), that results in the presentation of intracellular docking sites, and the recruitment and interaction with the Grb2/ Sos complex that activates the GTPase Ras that in turn recruits Raf to the cell membrane, where it too is activated. Once activated, Raf phosphorylates MEK1/2 that in turn phosphorylates ERK1/2 (Schlessinger, 2000) . In the lens and other tissues, a number of different RTK-antagonists have been identified, including Sprouty (Spry), Sef and Spred (Kramer et al., 1999; Tefft et al., 1999; Chambers and Mason, 2000; Boros et al., 2006; Shin et al., 2012; Zhao et al., 2015) . These different antagonists are reported to regulate ERK1/2-signaling at different levels (Kovalenko et al., 2003; Mason et al., 2006; Meng et al., 2012) .
Earlier studies in our laboratory with transgenic mice have revealed a putative role for ERK1/2 signaling during TGFb-induced EMT (Shin et al., 2012) . The deletion of Spry in the lens disrupts normal ERK1/2 signaling leading to aberrant lens cell transdifferentiation, with a rise in Smad-activation prior to an EMT that leads to cataract. Moreover, overexpression of Spry in the lens not only suppresses ERK1/2 signaling, but also TGFb signaling, effectively blocking EMT and the development of cataract (Shin et al., 2012) . TGFb-induced EMT in rat lens epithelial explants was also recently shown to be repressed when cells were transfected with other RTK-inhibitors, including Spred and Sef (Zhao et al., 2015) . TGFb-induced EMT can be suppressed through the inhibition of ERK1/2 signaling in different cellular contexts, such as primary human lens epithelial cells, SRA01/04 human lens epithelial cells, NMuMG epithelial cells, mouse cortical tubule (MCT) epithelial cells and HaCaT cells (Zavadil et al., 2001; Xie et al., 2004; Chen et al., 2014; Tiwari et al., 2016) . Taken together, these studies strongly suggest a requirement for ERK1/2 signaling in TGFbinduced EMT.
While TGFb-induced EMT is a well-defined process; the precise intracellular signaling events that drive EMT are yet to be fully elucidated. A role for non-canonical TGFb signal transduction is implicated in the EMT process and appears to be context and tissue specific. In the present study, we examine the role for ERK1/2 phosphorylation not only for the initiation of TGFb-induced EMT, but in the progression of this pathological process.
Materials and methods
Lens tissue was obtained from postnatal day 21 (P21) albino Wistar rats (Rattus norvegicus). All animal handling procedures were in accordance with the National Health and Medical Research Council (Australia), the ARVO statement for the Use of Animals in Ophthalmic and Vision Research and were approved by the Animal Ethical Review Committee of the University of Sydney, Australia.
Preparation of lens epithelial explants
Tissue collection and culture was carried out in fresh equilibrated (37 C, 5% CO 2 ) Medium 199 with Earl's salts (M199; Life Technologies, Waltham, MA, USA) supplemented with 50 mg/ml Lglutamine, 50 IU/ml penicillin, 50 mg/ml streptomycin, 2.5 mg/ml Amphotericin B (Life Technologies) and 0.1% bovine serum albumin (BSA; Sigma-Aldrich Corp., St. Louis, MO, USA). Explanting of the lens epithelium was carried out under sterile conditions with a dissecting microscope (Wild-Leitz, Switzerland). Explants were left to equilibrate (37 C, 5% CO 2 ) for at least 24 h prior to treatment.
Prior to treatment, media was replaced in all dishes with 1 ml of fresh medium. Human recombinant TGFb-2 (R&D Systems, Minneapolis, MN, USA) was used at 200 pg -1 ng/ml to induce EMT. The selective MEK1/2 inhibitor, UO126 (Promega, Madison, WI, USA), was used at 50 mM to block ERK1/2 activation (see Lovicu and McAvoy, 2001) . Explants were either pre-treated with UO126 2 h prior to the addition of TGFb (U/TGFb), or UO126 was added after the addition of TGFb at 2 h (TGFb/U2), 6 h (TGFb/U6), 24 h (TGFb/ U24) or 48 h (TGFb/U48). All experiments were repeated independently at least three times.
Phase contrast microscopy
Morphological changes were monitored daily using phase contrast microscopy (CK2, Olympus, Tokyo, Japan). Micrographs were obtained with a digital camera (Leica DFC-280, Leica, Wetzlar, Germany) and only explants that exhibited a tightly packed monolayer of cells at day 0 were included in the analysis.
In the present study the extent of visible lens capsule was used as a measure of cell loss, calculated as a percentage of the whole explant surface. At least 9 micrographs were obtained of each explant each day, and using Adobe Photoshop CS6, regions of bare lens capsule were filled to create a black and white image. The percentage of the total area of the lens capsule was analyzed using ImageJ. A two-way ANOVA with Tukey's post-hoc analysis was used to infer statistical significance.
SDS-PAGE and western blotting
At the end of the respective incubation periods, explants were collected, lysed and run through a 10% SDS-PAGE gel, as described previously (Zhao et al., 2015) . The PVDF membranes (Merck Millipore, Billerica, MA, USA) were incubated overnight at 4 C with the primary antibody diluted in blocking buffer (2.5% BSA/TBST or 5% skim milk/TBST). The antibodies used were against phospho-ERK1/ 2 (1:1000; Cell Signaling Technology, Danvers, MA, USA), total-ERK1/2 (1:1000; Cell Signaling Technology), phospho-Smad2 (Ser245/250/255; 1:1000; Cell Signaling Technology), phosphoSmad2/3 (Ser465/467 and Ser423/425 respectively; 1:1000; Cell Signaling Technology), total-Smad2/3 (1:1000; Cell Signaling Technology), a-smooth muscle actin (1:2000; Sigma-Aldrich Corp.), E-cadherin (1:1000, BD Transduction Laboratories, San Jose, CA, USA) and GAPDH (1:5000, Sigma-Aldrich). For subsequent quantification purposes, given their distinct size differences, p-ERK1/2, p-Smad2, p-Smad2/3 or a-sma were double-labeled with GAPDH on the same blot at the same time. Following an overnight incubation, HRP-conjugated anti-rabbit (1:5000; Cell Signaling Technology) or HRP-conjugated anti-mouse (1:10000; Zymed, USA) antibodies were used in conjunction with peroxidase solution and luminol reagent for enhanced chemiluminescence (ECL; Merck Millipore) to visualize the proteins under the ChemiDoc MP imaging system (Bio-Rad Laboratories, Hercules, CA, USA). The intensity of protein bands were analyzed using Image Lab software (Bio-Rad Laboratories), and all proteins of interest were normalized relative to corresponding GAPDH levels. An ANOVA with Tukey's or Dunnett's post hoc test was used to infer statistical differences between band intensities and presented as S.E.M., with a p < 0.05 considered statistically significant.
Immunofluorescent labeling
All immunofluorescent analysis of explants was carried out in the original culture dishes. At the conclusion of the culture period, media in dishes was replaced with 100% methanol to fix cells for 45 s and then rinsed with PBS five times in quick succession. Nonspecific binding was blocked with 10% normal goat serum (NGS) diluted in PBS supplemented with 1% BSA (PBS-BSA) for 1 h at room temperature. Explants were incubated with primary antibody, diluted in 1.5% NGS in PBS-BSA overnight at 4 C. The proteins that were visualized with immunofluorescent labeling were a-SMA
(1:100; Sigma-Aldrich Corp.) and E-cadherin (1:500; BD Transduction Laboratories). The following day, an Alexa594 (1:1000; Life Technologies, USA) secondary antibody diluted in PBS/BSA was applied for 2 h at room temperature. Cell nuclei were counterstained with 1 mg/ml Hoechst 33342 (Sigma-Aldrich Corp.), prior to mounting explants with 10% PBS in glycerol. Explants were imaged using confocal microscopy (Zeiss LSM 700; Carl Zeiss AG, Jena, Germany).
Quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR)
At the end of respective culture periods, explants were collected under RNAse-free conditions as described previously (Shu et al., 2017) . RNA (200 ng) was reverse-transcribed with the sensiFAST cDNA synthesis kit (Bioline, Alexandria, NSW, Australia). a-SMA primers spanning the exon-exon junction were used (see Shu et al., 2017) . All qRT-PCR reactions were executed with SensiFAST SYBR No-ROX (Bioline, Australia) in the LightCycler480 (Roche Diagnostics Ltd. Frorrenstrasse, Switzerland) as described previously (Shu et al., 2017) . Data was analyzed with GenEX 6.0 software (MultiD Analyses AB, Goteborg, Sweden). All experiments were carried out in triplicate, and each qRT-PCR reaction (including notemplate controls and minus RT controls) were carried out in duplicate. GraphPad Prism version 7.02 (Graphpad software, Inc.) was used for statistical testing. A two-way ANOVA followed by Tukey's post hoc test was used, with p < 0.05 considered statistically significant.
Results

Lens epithelial cells undergo TGFb-induced EMT
When treated with TGFb, lens epithelial explants underwent gross morphological changes associated with EMT. Untreated control explants remained as a tightly packed epithelial monolayer throughout the 5 day culture period (see Fig. 1A ). After 24 h of TGFb treatment (day 1) some cells elongated and presented tapered ends, consistent with a myofibroblastic phenotype ( Fig. 1B ; white arrows). This phenomenon was more pronounced on day 2 as the majority of cells present on lens explants were elongated and myofibroblastic (Fig. 1C) . Cellular blebbing, indicative of apoptosis was featured in explants at day 2 (Fig. 1C , arrowheads) and day 3 (Fig. 1D, arrowheads) . Consistent with this, areas of cell loss, as revealed by bare patches of the underlying lens capsule ( Fig. 2D ; asterisk), featured after 3 days of TGFb treatment. There was a 62% cell loss after 3 days of TGFb treatment ( Fig. 8 ) with clear visualization of capsular wrinkling ( Fig. 1D ; arrows). The entire exposed lens capsule was visible at day 4 and 5 of TGFb treatment, indicative of complete cell loss ( Fig. 1E and F).
TGFb phosphorylation of ERK1/2
Phosphorylation of ERK1/2 was induced by TGFb in lens epithelial explants. Western blot analysis showed that the first significant amplification of ERK1/2 activation was at 40 min following TGFb treatment. A 5-fold increase in ERK1/2 phosphorylation was then reached by 18 h of TGFb treatment (Fig. 2) . Following this peak at 18 h, the level of ERK1/2 phosphorylation remained elevated; however, it did not rise beyond the level seen at 18 h. A notable finding is that although the level of ERK1 and ERK2 phosphorylation varied throughout the culture period, TGFb treated explants consistently showed higher levels of ERK1/2 activation compared to untreated control explants.
Pre-treatment of lens epithelial explants with UO126 for 2 h prior to the addition of TGFb abolished all TGFb-induced ERK1/2 phosphorylation (Fig. 2) . To ensure that UO126 effectively blocked ERK1/2 signaling we examined its phosphorylation levels in all treatment groups after 3 days of culture. All groups that were treated with UO126, both pre-and post-TGFb-treatment displayed negligible levels of ERK1/2 activation after 3 days of culture (see Fig. 8A ).
TGFb-induced ERK1/2 can modulate Smad2 and Smad3 phosphorylation
A significant increase in the phosphorylation of the linker region of Smad2 was seen after 60 min treatment with TGFb (Fig. 2) . Pretreatment with UO126 prior to TGFb did not significantly alter the level of phosphorylation of the Smad2 linker at this time; however, at 18 h with UO126 pre-treatment, there was a significant reduction in TGFb-induced Smad2 phosphorylation (Fig. 2) . When we examined the activation of the C-terminal domain of Smad2 and Smad3 at this time point, TGFb-treatment significantly increased the activation of Smad2/3 and UO126 pre-treatment was able to suppress this activation (Fig. 3) . The reduction in Smad2/3 phosphorylation was not a reflection of total Smad2/3 protein reduction, given there was no significant change in total Smad2/3 levels between treatments. Likewise, total ERK1/2 protein levels also remained constant between different treatments (Fig. 3B) .
ERK1/2 signaling is required for the initiation of TGFb-induced EMT
Pre-treatment with UO126 inhibited the progression of TGFbinduced EMT in lens epithelial explants. In the presence of UO126, an epithelial monolayer was retained after 24 and 48 h post-TGFb treatment ( Fig. 4B and C) ; these explants did not display cell elongation typical of an EMT response. Blebbing of the cells, indicative of apoptosis, was still evident after 24 h of TGFb treatment ( Fig. 4B ; arrowhead) and remained present throughout the culture period up to 5 days. UO126 pre-treatment was sufficient in significantly reducing TGFb-induced cell loss (see Fig. 10 ). After 3 days of treatment with TGFb and UO126 (U/TGFb) only 28% cell loss was evident; however, most notably 45e48% cells remained at day 4 and 5 of treatment, compared to no cell loss evident in control explants, and a complete cell loss in TGFb-only-treated explants. While some evidence of capsular wrinkling was still observed in U/ TGFb explants ( Fig. 4E and F) , it was noted that the overall lens capsule displayed less wrinkling than that seen in explants treated with TGFb alone.
To determine the impact of UO126 on TGFb-induced EMT, we next examined for molecular changes in these cells. Some cells in untreated explants showed cytoplasmic a-SMA after 3 days of culture (Fig. 5A) ; however, when treated with TGFb, all cells in explants displayed pronounced a-SMA incorporation into stress fibers (Fig. 5C ). We found that UO126 alone completely abolished a-SMA expression (Fig. 5B) , and that pre-treatment with UO126
reduced TGFb-induced a-SMA expression levels, similar to that of control explants (Fig. 5D) . Western blot and subsequent densitometry analysis corroborated our immunofluorescent findings (Fig. 5E and F) .
Immunofluorescent labeling of E-cadherin localized to cell borders, in control and UO126-treated explants ( Fig. 5G and H) ; however, after 3 days treatment with only TGFb, E-cadherin dissociated from the cell borders and was more evident in the cytoplasm (Fig. 5I) . When explants were pre-treated with UO126 Fig. 1 . Representative phase contrast micrographs of lens epithelial explants treated with TGFb for up to 5 days. Explants not treated with TGFb exhibited a tightly packed monolayer (A). After 24 h (Day 1) of TGFb treatment (B), some cells began to elongate (white arrows). At 2 days post-treatment (C), there was more pronounced cell elongation (white arrows), and cellular blebbing was also evident (arrowheads, see also D). After 3 days of TGFb treatment (D), cell loss led to large areas of lens capsule exposed (asterisk), revealing capsular wrinkling (black arrows). At 4 (E) and 5 days (F), viable cells are mostly absent, with pronounced capsular wrinkling more visible (black arrows) on the bare capsule (Scale bar ¼ 100 mm).
prior to TGFb, E-cadherin was retained and visualized at the borders of cells (Fig. 5J) . While the epithelial membrane marker, E-cadherin, was found to be reduced in lens explants treated with TGFb when compared to control explants using western blotting, these differences were not statistically significant (Fig. 5E and K) .
Given we observed that TGFb induced significantly higher ERK1/ 2 phosphorylation at 40 min and this peaked at 18 h (Fig. 2) , we hypothesized that ERK1/2 activation up to 18 h was required for TGFb-induced EMT. To test this, explants received UO126, at select earlier time points after addition of TGFb, at 2 h (TGFb/U2) and at Fig. 2 . Western blot demonstrating TGFb-induced ERK1/2 phosphorylation and Smad2 phosphorylation up to 60 min (Ai) and up to 48 h (Aii), with or without UO126 pretreatment. Levels of phosphorylated ERK1/2 and Smad2 were quantified and normalized against GAPDH (B). UO126 pre-treatment abolished all TGFb-induced ERK1/2 signaling and modulated TGFb-induced Smad2 signaling. ANOVA with Dunnett's post-hoc test was used to quantify ERK1/2 phosphorylation relative to untreated controls, whereas ANOVA with Tukey's post-hoc test was used to analyze Smad2 phosphorylation. Error bars represent S.E.M., *p < 0.05; **p < 0.01; ****p < 0.0001. 6 h (TGFb/U6). The addition of UO126 at 2 and 6 h after TGFb treatment resulted in a complete suppression of ERK1/2 signaling by 3 days of culture ( Fig. 6A and D) . This was sufficient to block a-SMA accumulation into stress fibers shown after 3 days of culture ( Fig. 7G and J) , as well as overall protein levels demonstrated using western blots (Fig. 6A and C) . The level of E-cadherin protein appeared reduced in TGFb-treated explants (TGFb, TGFb/U2 and TGFb/U6) when compared to controls; however, these differences were not significant ( Fig. 6A and B) , with E-cadherin visualized at the borders of cells with immunofluorescent labeling (Fig. 7H and  K) . The morphology of cells in lens explants in TGFb/U2 and TGFb/ U6 groups after 3 days of culture was consistent with that of cells in U/TGFb explants ( Fig. 7I and L) .
ERK1/2 signaling is not required for the progression of EMT
To test whether ERK1/2 signaling after 18 h is required for the progression of TGFb-induced EMT, we added UO126 to lens epithelial explants, either at 24 h or 48 h after the addition of TGFb. After 24 h of TGFb treatment some cells began to show elongation, typical of the TGFb-induced EMT response (not shown). With application of UO126 at this time (TGFb/U24), these explants Fig. 3 . Representative western blots of explants treated for 18 h with TGFb with or without UO126 pre-treatment prior to TGFb. Phosphorylated-Smad2/3, total-Smad2/3, total-ERK1/2 and GAPDH are labeled (A). p-Smad2/3, t-Smad2/3 and t-ERK1/2 were normalized against GAPDH (B; error bars represent S.E.M.). ANOVA with Sidak's post-hoc test was used to analyze data (*p < 0.05; **p < 0.01; ****p < 0.0001).
retained some elongated cells 24 h later, at day 2 of culture ( Fig. 8B ; arrowheads), and cellular blebbing was also evident at this time ( Fig. 8B ; white arrows). After 3 days of culture, no elongated cells were present; however, TGFb/U24 explants showed small patches of bare capsule, indicative of cell loss ( Fig. 8C; asterisk) . Most notably, at days 4 and 5 of treatment these explants exhibited a reduction (40e46%) in cell loss ( Fig. 8D and E) similar to explants that were pre-treated with UO126. Explants that were treated with TGFb alone had already undergone complete cell loss by day 4 of culture (see Fig. 10 ). Evidence of capsular wrinkling was observed; however, this was again less apparent to that seen in TGFb-treated explants.
After 48 h, the process of TGFb-induced EMT is well established in lens explants. When treated with UO126 at this time (TGFb/U48) it is not sufficient in stopping the morphological changes associated with EMT ( Fig. 8F and G) . At day 3 (24 h after the addition of UO126), explants exhibited 65% cell loss and 91% at day 4 (Fig. 10) , exposing the majority of the underlying wrinkled lens capsule, consistent with a TGFb-induced EMT.
Blocking ERK1/2 signaling at 24 and 48 h after the addition of TGFb did not block a-SMA incorporation into stress fibers ( Fig. 9C and D). Western blot and subsequent densitometry analysis supported these immunofluorescent findings ( Fig. 9E and F) . In these treatment groups, evidence of membrane labeling of E-cadherin is seen at some of the cell borders ( Fig. 9I and J) . When the level of Ecadherin was assessed with western blotting, while it appeared higher in explants that received UO126 at 24 and 48 h than those treated with TGFb alone, these differences were not statistically significant ( Fig. 9E and K) . After 5 days of treatment, explants cultured in control media (no TGFb) remained as a tightly packed monolayer (Fig. 11A) . Likewise, explants cultured with UO126 over 5 days did not undergo any morphological changes (Fig. 11B ) and the addition of UO126 alone to media at 2, 6, 24 or 48 h into the culture period also did not lead to any morphological changes over the 5-day-culture period (see Fig. 11CeF ). Representative immunofluorescent images of a-SMA and E-cadherin labeling of lens epithelial explants after 3 days culture with TGFb, with or without UO126 pretreatment. Control explants showed some cytoplasmic labeling of a-SMA (red) after 3 days (A). UO126 treatment alone completely abolished any a-SMA labeling (B). TGFb treatment for 3 days led to prominent a-SMA expression associated with stress fibers (C). Pre-treatment with UO126 prior to TGFb demonstrated labeling for a-SMA similar to that seen in control explants (D). Representative western blot analysis verified the immunolabeling results (E; top panel), with reduced a-SMA labeling in the presence of UO126. Densitometry analysis of western blots demonstrated a significant decrease in a-SMA expression in UO126 pre-treated explants when compared to those treated with TGFb alone (F; a-SMA was normalized against GAPDH; error bars represent S.E.M.). E-cadherin was visualized at the cell borders of control explants and those treated with UO126 (G, H).
Treatment with TGFb led to a loss of this membrane labeling of E-cadherin (I). Pre-treatment with UO126 retained E-cadherin at the cell borders following TGFb treatment (J; Scale bar ¼ 20 mm). Corresponding western blot analysis of E-cadherin (E, middle panel) showed no significant changes in levels of protein (K; E-cadherin was normalized against GAPDH; error bars represent S.E.M.). ANOVA with Tukey's post-hoc test was used to analyze data (**p < 0.01; ***p < 0.001).
a-SMA gene expression
To better understand why blocking ERK1/2 signaling before 24 h of TGFb addition was more sufficient in blocking a-SMA stress fiber association, qRT-PCR was performed to examine changes in a-SMA gene expression. It was found that the highest level of a-SMA expression was seen after 24 h of TGFb-treatment. This peak (5-fold increase compared to control cells) in a-SMA expression in cells treated with TGFb reduced after this time (Fig. 12) . Pre-treatment with UO126 alone abolished all a-SMA expression, consistent with earlier western blot and immunofluorescent labeling (see Fig. 5 ). Pre-treatment with UO126 reduced TGFb-induced a-SMA expression. The addition of UO126 at 24 h post-TGFb treatment reduced TGFb-induced a-SMA expression at days 2 and 3; however, post-treatment with UO126 at 48 h was not sufficient in reducing a-SMA expression at day 3.
Discussion
In the present study, we have shown that TGFb is able to activate ERK1/2 signaling in lens epithelial explants, and that this is MEK1/2 -dependent, as pharmacological inhibition with UO126 was able to abolish all ERK1/2 phosphorylation. ERK1/2 is a multifunctional signaling molecule, and in the lens it has been shown to be correlated with cell proliferation and differentiation, dependent on its duration of activity and intensity (Lovicu and McAvoy, 2001; Le and Musil, 2001) . The lens epithelium is exposed to a multitude of aqueous-derived growth factors in situ such as FGF, IGF, PDGF and EGF, that when applied to lens epithelial explants in vitro are able to induce different ERK1/2 signaling profiles that can all lead to cell proliferation (Iyengar et al., 2007 (Iyengar et al., , 2009 ). RTK-antagonists, Spry, Spred and Sef, regulate ERK1/2 signaling and have been identified in the lens (Boros et al., 2006; Shin et al., 2012; Zhao et al., 2015) . Given that transfection of lens epithelial explants with Spry, Spred or Sef constructs are able to inhibit TGFb-induced EMT (Zhao et al., 2015) , and the overexpression of Spry in the lens can rescue the cataractous phenotype present in TGFb-overexpressing mice (Shin et al., 2012) , it is clear that ERK1/2 signaling may also contribute to the process of TGFb-mediated EMT. This is the first study to directly examine the temporal role of ERK1/2 signaling during TGFbinduced lens EMT.
We have shown that TGFb significantly increased the phosphorylation of ERK1/2 from 40 min, indicative of an indirect effect. Interestingly, phosphorylation of the Smad2 linker region, known Fig. 6 . Representative western blots of E-cadherin, a-SMA and phosphorylated ERK1/2 after 3 days of culture of explants treated with UO126, added 2 (TGFb/U2) or 6 h (TGFb/U6) after TGFb addition (A). No significant differences in E-cadherin levels were found between treatment groups (B; E-cadherin was normalized against GAPDH; error bars represent S.E.M.). Analysis of a-SMA levels showed a significant decrease in both TGFb/U2 and TGFb/U6 explants when compared to those cultured with TGFb alone (C; a-SMA was normalized against GAPDH; error bars represent S.E.M.). The addition of UO126 at 2 and 6 h post-TGFb-treatment significantly reduced the expression of phosphorylated ERK1/2 up to 3 days when compared to the untreated control (D; p-ERK1/2 was normalized against GAPDH; error bars represent S.E.M.). ANOVA with Tukey's post-hoc test was used to analyze data (*p < 0.05; **p < 0.01; ***p < 0.001).
to interact with ERK1/2 (Shi and Massague, 2003) , occurred after the increase in ERK1/2 signaling at 60 min. TGFb has been shown previously to activate ERK1/2 signaling in lens cell lines such as primary human lens cells (Tiwari et al., 2016) , FHL124 (Dawes et al., 2009 ) and SRA01/04 (Chen et al., 2014) . In SRA01/04 cells, TGFbinduced ERK1/2 signaling was shown to be upstream of Smad2/3 (Chen et al., 2014) . Similarly, in other cellular contexts, such as NIH/ 3T3 fibroblast cells TGFb-induced ERK activity has been shown to be necessary for Smad activation (Li et al., 2009) , whereas in Swiss3T3 and Balb3T3 cells, TGFb failed to activate ERK signaling despite stimulating growth in these quiescent cells (Chatani et al., 1995) . In rat mesangial cells, TGFb-induced collagen IV synthesis is synergistically produced by the interaction between ERK1/2 and Smad2/3 (Jiang et al., 2010) . The mechanism of crosstalk between the ERK1/2 and Smad2/3 signaling pathways appears to be cell context dependent. In the current study we found that in lens epithelial explants, Smad2 linker activation occurs after TGFbinduced ERK1/2 phosphorylation; however, UO126 pre-treatment did not appear to modulate TGFb-induced phosphorylation of this linker at the earlier time point of 40 min. Given that UO126 pretreatment significantly reduced TGFb-induced Smad2 linker phosphorylation only at 18 h (when TGFb-induced ERK1/2 Fig. 7 . Representative micrographs of explants treated with TGFb and post-treated with UO126 at 2 (TGFb/U2) and 6 h (TGFb/U6), after 3 days. Control explants demonstrated a low level of a -SMA, not associated with stress fibers (A) and E-cadherin localized to cell borders (B), consistent with an epithelial phenotype (C). After 3 days treatment with TGFb, a-SMA was localized to stress fibers (D) and E-cadherin was dissociated from the cell borders (E), consistent with lens epithelial cells undergoing EMT (F). UO126 addition after 2 h of TGFb treatment was sufficient in maintaining a low level of a-SMA, not associated with stress fibers (G), and retaining E-cadherin at the cell borders (H), consistent with an epithelial phenotype (I). Non-stress fiber a-SMA (J), and E-cadherin localization at the cell membrane (K) was also featured in explants treated with UO126, 6 h after the addition of TGFb (L). Scale bars are 20 mm (a-SMA and E-cadherin panels) and 100 mm (phase contrast).
phosphorylation was highest), we further examined the activation of the C-terminal domain of Smad2 and Smad3 at this same time. TGFb-induced Smad2/3 phosphorylation was significantly reduced with UO126 pre-treatment indicating that ERK1/2 may indeed facilitate the phosphorylation of Smad2/3. There is a significant reduction of TGFb-induced phosphorylation of the Smad 2 linker and C-terminal regions of Smad2/3 in the presence of UO126. Given that it is not a complete blockage of TGFb-signaling, indicates that Fig. 8 . Representative western blot of TGFb-induced ERK1/2 activation in lens epithelial explants cultured for 3 days with UO126 added prior to, or after 24 or 48 h of TGFb treatment (A; pERK1/2 was normalized against GAPDH; error bars represent S.E.M.; ANOVA with Tukey's post-hoc test was used to analyze data; *p < 0.05; ***p < 0.001). The addition of UO126, 24 h after TGFb, inhibited the progression of EMT (BeE). After 2 days of culture (B), some cell elongation was present (white arrows), as was cell blebbing (arrowheads). By day 3 some cell loss is evident (D, asterisk), and is more pronounced at day 4 (D) and 5 (E), exposing more of the underlying lens capsule (asterisk). When explants were treated with TGFb, and UO126 was added at 48 h, cell elongation (white arrow) was still evident at day 3 (F), as was cell loss that exposed the lens capsule (asterisk), revealing the underlying lens capsular wrinkling (black arrows). By day 4 of culture there was complete cell loss (G). Fig. 9 . Representative images of a-SMA and E-cadherin labeling when UO126 is added to lens epithelial explants 24 or 48 h after TGFb. Control explants exhibited low levels of a-SMA expression after 3 days of culture (A). When treated with TGFb, a-SMA fiber accumulation is prominent in stress fibers (B). Treatment with UO126 at 24 h (C, TGFb/U24) and 48 h (D, TGFb/U48) was not sufficient in blocking this TGFb-induced a-SMA labeling. Representative western blots showed that after 3 days of TGFb treatment, irrespective of UO126 post-treatment, a-SMA protein levels remained elevated relative to the untreated control (E, upper panel) . Densitometry analysis demonstrated a significant increase in a-SMA expression in explants treated with TGFb alone and TGFb/U24 and TGFb/U48 explants, when compared to the control (F; a-SMA was normalized against GAPDH, error bars represent SEM; ANOVA with Tukey's post-hoc test was used to analyze data; *p < 0.05; **p < 0.01). E-cadherin was visualized at cell borders after 3 days of culture in control explants (G). After 3 days of culture with TGFb alone, E-cadherin was no longer present at cell borders (H). When UO126 was added 24 h post TGFb treatment (I), E-cadherin labeling was present at some cell borders, and this was also seen in explants that received UO126 48 h post TGFb treatment (J; Scale bar ¼ 20 mm). Representative western blots of Ecadherin levels (E, middle panel) revealed no significant difference between treatment groups (K; E-cadherin was normalized against GAPDH; error bars represent S.E.M.; ANOVA with Tukey's post-hoc test was used to analyze data). Fig. 10 . Summary of cell loss in explants treated without TGFb (control), with UO126, TGFb, U/TGFb, TGFb/U24 and TGFb/U48 over 5 days. Trends revealed that TGFb and TGFb/U48 had similar rates in cell loss. U/TGFb and TGFb/U24 exhibited a similar progression of cell loss (error bars represent SEM; ANOVA with Tukey's post-hoc test was used to analyze data; *p < 0.05, **p < 0.01, ****p < 0.0001; when compared to control group). Cell loss was expressed as a percentage of bare capsule appearance (i.e. 100% bare capsule corresponds to 100% cell loss). Fig. 11 . Representative phase contrast micrographs of explants at day 5, cultured with media only (A; control), UO126 pre-treatment (B), control media with U0126 added after 2hr (C), control media with U0126 added after 6hr (D), control media with U0126 added after 24hr (E) and control media with U0126 added after 48hr (F). Scale bar ¼ 100 mm.
Smad signaling in lens epithelial explants occurs in parallel through both ERK1/2-dependent and -independent mechanisms. TGFb-induced ERK1/2 signaling has been implicated in a-SMA stress fiber labeling in SRA01/04 lens cells (Chen et al., 2014) and LLC-PK1/AT1 porcine proximal tubular epithelial cells (Sebe et al., 2008) . Likewise, in human lens cells, pharmacological inhibition of ERK1/2 signaling was sufficient in reducing TGFb-induced a-SMA expression (Tiwari et al., 2016) . In FHL124 lens cells, TGFb-induced upregulation of a-SMA was shown to be independent of Smad4 (Dawes et al., 2009) . These findings coincide with the current study where a-SMA protein expression was reduced by pre-treatment with UO126; however, this is the first study to show a clear role for ERK1/2 in the initiation of a-SMA stress fiber association. We found that early inhibition of ERK1/2 signaling, either prior to or 2 and 6 h after TGFb treatment, blocked the upregulation of a-SMA and its subsequent association with stress fibers during TGFbinduced EMT. This coincided with the peak of a-SMA expression found 24 h after TGFb treatment. Blocking ERK1/2 signaling 24 or 48 h into the TGFb-induced EMT process was not sufficient in preventing a-SMA accumulation into stress fibers. As it has been recently shown that tropomyosin facilitates the incorporation of a-SMA into stress fibers in human myofibroblasts (Prunotto et al., 2015) , it would be of interest to examine how ERK1/2 influences tropomyosin in lens EMT. Silencing of a-SMA expression in FHL124 cells led to an increased contractility in response to TGFb (Dawes et al., 2008 (Dawes et al., , 2009 . The uncoupling of a-SMA and cell contractility was also evident in the present study, as capsular wrinkling was less evident in U/TGFb and TGFb/U24 explants despite strong a-SMA labeling at day 3 in TGFb/U24 and not in U/ TGFb explants.
The expression of E-cadherin has been shown to be negatively regulated by, and dependent on the transcription factor Snail (Cano et al., 2000) . In a rat whole lens model, TGFb was found to increase the expression of Snail mRNA in subcapsular plaques (Nathu et al., 2009) . In transgenic mice, TGFb-overexpression, or deletion of the RTK/ERK1/2 antagonist Spry in the lens led to an increase in Snai1 and Snai2 labeling in cell nuclei. This was not present in mice cooverexpressing Spry and TGFb, implicating ERK1/2 signaling in TGFb-mediated Snai1 activation and subsequent E-cadherin down regulation (Shin et al., 2012) . The loss of cell-cell contact is thought to facilitate the process of EMT; as has been highlighted in colorectal cancer biopsies where there is a negative correlation between E-cadherin loss and a-SMA expression (Valcz et al., 2012) . In contrast we found that post-treatment with UO126 at 24 and 48 h after TGFb treatment was not able to suppress a-SMA fiber formation; however, it permitted the retention of some E-cadherin at cell borders. In the context of lens epithelial cells, it appears that a-SMA expression and cell membrane localization of E-cadherin are not mutually exclusive. Although a-SMA expression is dependent on early TGFb-mediated ERK1/2 signaling, it appears that cell-cell adhesion may not be heavily dependent on ERK1/2 signaling. It is possible that ERK1/2 may interact with other signaling pathways to contribute to the loss of cell-cell contact, for example, ZO-1 and Ecadherin dissociation has been linked to TGFb-induced P13K/Akt signaling in NMuMG cells (Bakin et al., 2000) .
Cell loss, highlighted by changes in the area of exposed lens capsule in this study, was significantly reduced and comparable in U/TGFb and TGFb/U24 explants, indicating that TGFb-induced ERK1/2 signaling may facilitate cell death in the earlier stages of culture. Blocking ERK1/2 signaling 48 h after TGFb treatment was not sufficient in reducing TGFb-mediated cell loss, indicating that ERK1/2 is not necessary for the progression of cell loss after 48 h. While UO126 was able to reduce cell loss in U/TGFb and TGFb/U24 explants, it did not stop the process of cell death completely, indicating that ERK1/2 may potentially interact with other signaling pathways to contribute to cell loss. For example, in NMuMG cells, TGFb-mediated apoptosis has been shown to be dependent on p38 signaling (Yu et al., 2002) . TGFb also promotes the upregulation of Smad7 (Yan et al., 2009 ) that in mesangial cells, has been attributed to activation of caspase-3 during TGFb-mediated apoptosis. This apoptosis was dependent on Smad7 and not Smad2 or Smad3 (Okado et al., 2002) . Mean fold changes in expression of a-SMA over 3 days, normalized against GAPDH expression (A; error bars represent S.E.M). UO126 reduced a-SMA expression. ANOVA followed by Tukey's post-hoc test was used to infer statistical significance (B; *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001).
Overall, here we show that ERK1/2 signaling is required for the initiation of TGFb-induced EMT in the lens, but not its progression. We show that earlier suppression of ERK1/2 signaling is more effective at inhibiting TGFb-induced EMT, and as EMT progresses, it becomes less dependent on ERK1/2. This highlights the important function of normally expressed antagonists in the lens such as Spry, Spred and Sef that are known to negatively regulate ERK1/2 signaling. Their maintenance in the lens throughout life, not only to tightly regulate ERK1/2 signaling, may protect the lens from aberrant TGFb signaling that leads to age-related cataract. This temporal relationship of TGFb-induced ERK1/2 and EMT progression may have novel implications for the better understanding and potentially the treatment of cataract.
